Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
NCT ID: NCT00353678
Last Updated: 2013-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
1141 participants
INTERVENTIONAL
2006-06-30
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery
NCT00913120
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
NCT00408239
Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities
NCT00937911
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
NCT00902928
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM150
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or over
* Written informed consent obtained
Exclusion Criteria
* Subjects considered at increased risk of bleeding
* Surgery planned for contralateral hip at the same time or within 10 weeks after enrolment
* Concomitant use of anticoagulants/ antiplatelet agents
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Astellas Pharma Europe B.V., Medical Clinical Development
Role: PRINCIPAL_INVESTIGATOR
Department of Orthopedics, Surgical Sciences, Gothenburg University Sahlgrenska/ÖSTRA University Hospital, Goteborg, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Innsbruck, , Austria
Vienna, , Austria
Vienna, , Austria
Foča, , Bosnia and Herzegovina
Sarajevo, , Bosnia and Herzegovina
Tuzla, , Bosnia and Herzegovina
Brno, , Czechia
Kladno, , Czechia
Prague, , Czechia
Třebíč, , Czechia
Copenhagen, , Denmark
Herlev, , Denmark
Hørsholm, , Denmark
Silkeborg, , Denmark
Jyväskylä, , Finland
Oulu, , Finland
Berlin, , Germany
Frankfurt am Main, , Germany
Halle, , Germany
Kremmen OT Somerfeld, , Germany
Markgröningen, , Germany
Schwandorf in Bayern, , Germany
Athens, , Greece
Melíssia, , Greece
Bologna, , Italy
Milan, , Italy
Milan, , Italy
Parma, , Italy
Pavia, , Italy
Pietra Ligure, , Italy
Reggio Emilia, , Italy
Rozzano, , Italy
S. Donato Milanese, , Italy
Udine, , Italy
Riga, , Latvia
Riga, , Latvia
Valmiera, , Latvia
Kaunas, , Lithuania
Vilnius, , Lithuania
Elverum, , Norway
Trondheim, , Norway
Tynset, , Norway
Bialystok, , Poland
Katowice, , Poland
Krakow, , Poland
Lublin, , Poland
Lublin, , Poland
Warsaw, , Poland
Chelyabinsk, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Nizhny Novgorod, , Russia
Orenburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Samara, , Russia
Volgograd, , Russia
Belgrade, , Serbia
Kragujevac, , Serbia
Niš, , Serbia
Novi Sad, , Serbia
Subotica, , Serbia
Banska Bysterica, , Slovakia
Ružomberok, , Slovakia
Cantoria, , Spain
Castellon, , Spain
Cáceres, , Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Valencia, , Spain
Falköping, , Sweden
Gothenburg, , Sweden
Kalmar, , Sweden
Motala, , Sweden
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kalebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost. 2010 Apr;8(4):714-21. doi: 10.1111/j.1538-7836.2010.03748.x. Epub 2010 Jan 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
150-CL-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.